All In Biotech

Drug Trial Radar · NCT07503405

Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model

A Phase 2a, Single-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tivoxavir Marboxil (TRX-100) in Healthy Adults in a Human Influenza A Challenge Model

Last checked: Nov 19, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 165 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

165

Planned (sponsor's estimate)

Start

Jun 2026

Primary completion

Nov 2026

Study completion Apr 2027

Sponsor

Lead sponsor
Traws Pharma, Inc.Industry
Sponsor type
Industry
First posted
Mar 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This will be a randomized, double-blind, placebo-controlled proof of concept study to evaluate the prophylactic efficacy and safety of orally administered TRX-100 in healthy adults challenged with influenza A/France/759/2021 (H1N1) virus.

Conditions

  • Influenza

Interventions

  • TRX-100Drug

    A single oral dose in capsules

  • PlaceboDrug

    A single oral dose in capsules

  • Influenza A/France/759/2021 (H1N1) virusBiological

    A single dose of challenge agent will be delivered Intranasal

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Laboratory-Confirmed InfectionTime frame: From Day 1 (pm) up to Day 8 (am)
  2. Symptoms of Grade ≥2Time frame: From Day 1 (am) to Day 8 (am)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • hVIVO Services Limited

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.